Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 1,347 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $64,656.00. Following the sale, the senior vice president now directly owns 114,147 shares of the company's stock, valued at $5,479,056. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Paula Green also recently made the following trade(s):
- On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $246,147.40.
- On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92.
- On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10.
- On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $13,941.18.
Twist Bioscience Trading Down 6.1 %
2024's Must-Watch Stocks!
From Darwin | Ad
Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
[Unlock Your Report Now]
Shares of NASDAQ:TWST opened at $42.49 on Thursday. Twist Bioscience Co. has a 1-year low of $18.59 and a 1-year high of $60.90. The firm has a market capitalization of $2.49 billion, a PE ratio of -11.12 and a beta of 1.78. The business's 50 day moving average is $43.92 and its 200-day moving average is $45.93.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on TWST shares. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research report on Monday, August 5th. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a research report on Monday, August 5th. Finally, Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $51.22.
Read Our Latest Stock Report on TWST
Institutional Trading of Twist Bioscience
Institutional investors have recently modified their holdings of the company. Signaturefd LLC grew its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. grew its holdings in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the 2nd quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after buying an additional 381 shares in the last quarter.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
